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time was 66.0 days [95% confidence interval (CI) 44.8–87.2] 
for patients with baseline CTC positivity and 138.0 days (95% 
CI 124.1–151.9) for CTC-negative patients (p = 0.01, log-rank 
test).  Conclusion: Our results suggest that in addition to the 
current prognostic methods, CTC analysis represents a po-
tential complementary tool for prediction of outcome in 
pancreatic cancer patients.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Pancreatic cancer is the 10th most commonly diag-
nosed cancer and has the highest mortality rate, as 96% 
of the patients diagnosed with this malignancy die with-
in the first 5 years  [1] . Pancreatic cancer lacks early symp-
toms and is, as a consequence, often diagnosed at a late 
stage when disease has spread to neighboring tissues, be-
yond the treatment window of curative resection  [2] . The 
inaccessibility of the pancreas further limits the possibil-
ity of surgical removal, and the aggressive nature of the 
tumor leads to a rapid progression that is strongly resis-
tant to chemotherapy  [3] . Moreover, the conventional 
prognostic indicators to predict patient outcome are of-
ten imperfect, owing mainly to tumor plasticity and sub-
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 Abstract 
 Objective: The aim of this study was to develop an immuno-
magnetic/real-time reverse transcriptase polymerase chain 
reaction (RT-PCR) assay and assess its clinical value for the 
molecular detection of circulating tumor cells (CTCs) in pe-
ripheral blood of pancreatic cancer patients.  Methods: The 
presence of CTCs was evaluated in 34 pancreatic cancer pa-
tients before systemic therapy and in 40 healthy controls, 
through immunomagnetic enrichment, using the antibod-
ies BM7 and VU1D9 [targeting mucin 1 and epithelial cell ad-
hesion molecule (EpCAM), respectively], followed by real-
time RT-PCR analysis of the genes  KRT19 ,  MUC1 ,  EPCAM , 
 CEACAM5 and  BIRC5.  Results: The developed assay showed 
high specificity, as none of the healthy controls were found 
to be positive for the multimarker gene panel. CTCs were 
detected in 47.1% of the pancreatic cancer patients before 
the beginning of systemic treatment. Shorter median pro-
gression-free survival (PFS) was observed for patients who 
had at least one detectable tumor-associated transcript, 
compared with patients who were CTC negative. Median PFS 
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jective assessment criteria  [4] . Therefore, there is an ur-
gent need for the establishment of new sensitive prognos-
tic methods capable of identifying patients with a worse 
prognosis or those destined to progress quickly.
 During recent years, the analysis of circulating tumor 
cells (CTCs) has become a promising diagnostic tool in 
oncology. However, although the prognostic value of 
CTCs has been extensively studied in breast, colorectal 
and prostate cancer  [5–11] , its role in pancreatic cancer is 
still poorly investigated. To date, only a few studies have 
assessed CTCs in peripheral blood (PB) of pancreatic 
cancer patients, with most of the published work report-
ing small cohorts, low CTC positivity rates and contra-
dictory results  [12] . 
 In the present study, we have employed immunomag-
netic enrichment and real-time reverse transcriptase 
polymerase chain reaction (RT-PCR) as the methodolog-
ical basis for the development of a CTC detection meth-
od. Our goal was to create an accurate assay that would 
improve the detection of CTCs in PB of pancreatic cancer 
patients and, at the same time, avoid false-positive re-
sults. Moreover, we aimed to evaluate whether CTC de-
tection could be used as a tool to refine prognosis in pan-
creatic cancer management. 
 Patients and Methods 
 Patient Selection and PB Sampling 
 Written informed consent was obtained from all participants, 
and the study was approved by the local medical ethical commit-
tee. The principal inclusion criteria were as follows: patients with 
histologically and radiographically proven pancreatic adenocar-
cinoma, initiating any first- or second-line systemic therapy. Pa-
tients with a history of previous malignancy and patients with 
active infection were excluded.
 Whole blood samples (10.0 ml) were collected into EDTA 
tubes from all subjects before therapy (Sarstedt AG & Co., Nüm-
brecht, Germany), and CTCs were isolated within 4 h of specimen 
collection. A group of healthy, anonymous control subjects, who 
were randomly selected from hospital staff, were asked to par-
ticipate in the study, and blood sampling was performed as de-
scribed above. 
 Patient Follow-Up 
 Patients underwent chemotherapy as appropriate for their di-
agnosis and disease evaluation by their medical oncologist ac-
cording to the institutional guidelines. The evaluation included a 
physical examination, a complete blood count, blood chemical 
tests, screening for serum tumor markers, radiography, computed 
tomographic scan and magnetic resonance imaging according to 
tumor type and stage. The planned reevaluation for patients with 
metastatic disease was performed every 3 months. Response was 
evaluated according to the clinical criteria codified by the Re-
sponse Evaluation Criteria in Solid Tumors  [13] by a team of med-
ical oncologists and radiologists. Each disease assessment was 
classified as a complete response, partial response, stable disease 
or progressive disease. The primary end point for metastatic pa-
tients was time to progression. For response to therapy in the met-
astatic setting, the favorable group was defined as having nonpro-
gressive disease (complete response, partial response and stable 
disease categories), and the unfavorable group was defined as 
those patients who suffered progressive disease or death.
 CTC Isolation from Blood Samples  
 CTCs were isolated from PB using 200   l of BM7/VU1D9 an-
tibodies coupled directly to immunomagnetic 4-  m Dynabeads  
(Invitrogen, Karlsruhe, Germany). Beads were incubated with the 
PB on a low-speed rotating device for 20 min at room tempera-
ture, after which labeled cells were separated using an external 
magnetic particle concentrator. The bead fraction was washed 5 
times with phosphate-buffered salt solution, and the retained mu-
cin 1-positive and/or epithelial cell adhesion molecule (EpCAM)-
positive cells were lysed in 400   l of Tris-HCl lysis buffer (includ-
ed in the Dynabeads mRNA Direct TM Kit, Invitrogen) and stored 
at –85  °  C until mRNA isolation and cDNA synthesis.
 mRNA Isolation and cDNA Synthesis 
 mRNA isolation from the lysed enriched cells was performed 
with the Dynabeads mRNA Direct Kit according to the manufac-
turer’s instructions. Sensiscript  Reverse Transcriptase (Qiagen, 
Hilden, Germany), recommended for first-strand cDNA synthe-
sis using  ! 50 ng RNA, was used for reverse transcription of the 
isolated and purified mRNA in combination with the Dynabeads 
oligo(dT) 25 (Invitrogen), according to the manufacturer’s guide-
lines. Reverse transcription was performed in 0.5   l of RNasin  
Ribonuclease Inhibitor (40 U/  l; Promega, Mannheim, Germa-
ny), 4   l of reverse transcriptase buffer, 4   l of dNTPs (5 m M each) 
and 2   l of Sensiscript Reverse Transcriptase and synthesized in 
a thermocycler under the following conditions: 60 min at 37   °   C 
followed by 5 min at 93  °  C. The resulting 40   l of cDNA was stored 
at –20  °  C until further use.
 Multimarker Real-Time PCR Analysis 
 Reverse transcription resulted in cDNA which was the tem-
plate for tumor cell detection and characterization by real-time 
PCR. The analysis of tumor-associated mRNA isolated from 
CTCs was performed for 5 tumor-associated transcripts : KRT19 , 
 MUC1 ,  EPCAM ,  CEACAM5 and  BIRC5 . Primers were selected 
using the Universal ProbeLibrary  system, and their sequences 
can be seen in  table 1 . The selected primers were designed to be 
intron spanning (exon specific) so as to eliminate reactivity with 
genomic DNA. The amplification of  ACTB (primers: forward, 5  -
GAAGAGCCAAGGACAGGTAC-3  ; reverse, 5  -CAACTTCAT-
CCACGTTCACC-3  ) served as a reference internal control and 
was used to verify the integrity of the RNA and the quality of the 
samples. PCR amplifications were performed on the Rotor-Gene 
3000 in a total volume of 25   l. Each reaction contained 12.5   l 
of the reaction buffer MESA FAST qPCR MasterMix Plus for 
SYBR  assay (Eurogentec, Cologne, Germany), including dNTPs 
(together with dUTP), Meteor Taq DNA polymerase, MgCl 2 
(4 m M final concentration), SYBR Green I and stabilizers, 0.1   l 
of each primer (100 pmol/  l), 2   l of cDNA and 10.3   l of RNase-
free H 2 O. The thermal profile used for real-time PCR was as fol-
lows: after a 5-min denaturation at 95   °   C, 40 cycles were carried 
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out with denaturation at 95   °   C for 5 s, annealing at 59   °   C for 20 s 
and extension at 72  °  C for 12 s. 
 PCR efficiency, linearity and sensitivity for each gene were val-
idated with a standard curve constructed from a simultaneously 
run serially diluted cDNA pool of human PB lymphocytes (PBLs) 
and the tumor cell line ZE, which expresses all the gene markers 
analyzed in this assay. Negative controls included samples with-
out reverse transcriptase and samples in which cDNA was re-
placed with genomic DNA. All values were obtained from the 
quantitative cycle (Cq) at which the increase in SYBR green fluo-
rescent signal associated with an exponential increase in PCR 
products reached the fixed threshold value of 0.25.
 Random PCRs were analyzed by gel electrophoresis in order 
to determine the specificity of the assay and ensure that with the 
PCR conditions and the different primer sets used, the product of 
the expected size was amplified. 
 Data Analysis 
 Taking into consideration all the limitations presented by rel-
ative and absolute quantification strategies, we used real-time RT-
PCR to detect the presence of a gene rather than to quantify it 
accurately. This approach is referred to as qualitative RT-PCR. 
However, in order to obtain an accurate yes/no answer, informa-
tion about the analytical sensitivity of the real-time RT-PCR assay 
must be determined  [14] . In the present study, we adopted the ap-
proach proposed by Caraguel et al.  [15] . According to these au-
thors, the analytical sensitivity of PCR, also referred to as the low-
er limit of detection, is defined as the minimum concentration of 
analyte detected at which 50% of the tested samples are positive 
and fit within the linear dynamic range of the reaction. Therefore, 
to demonstrate that the assay detects at least 50% of samples at a 
specified concentration with 95% confidence, a standard curve 
needs to be constructed and 5 replicates per dilution must be test-
ed. The analytical sensitivity is then estimated as the last serial 
linear concentration that yielded positives in all 5 replicates, 
meaning that the 95% confidence interval (CI) for the probability 
of testing positive is 47.8–100%. The corresponding Cq value ob-
tained as the lower limit of detection for each gene is selected as 
the analytical cutoff. Any Cq value above this defined limit is con-
sidered not reliable. In the present study, serial 10-fold dilutions 
of a cDNA pool of human PBLs and ZE tumor cells were used to 
construct the standard curves.
 Statistical Analysis 
 The linearity, efficiency and analytical sensitivity of the real-
time RT-PCR assay were assessed by linear regression analysis. 
Standard curves were constructed for each marker, and from the 
equation obtained after regression analysis, the following param-
eters were determined: sensitivity, given by the y intercept; linear-
ity, expressed as the correlation coefficient (R 2 ), and efficiency of 
the assay, determined by the slope of the log-linear phase of the 
amplification reaction. 
 The clinical utility of CTC detection in pancreatic cancer pa-
tients was assessed by means of survival analysis. Progression-
free survival (PFS) was defined as the time between the baseline 
CTC assessment (the initiation of treatment) and the documenta-
tion of first radiographic disease progression or death. Patients 
who were alive and progression free at the time of analysis were 
censored using the time between the baseline CTC assessment 
and their most recent follow-up evaluations. PFS in CTC-positive 
and CTC-negative groups was compared with the Kaplan-Meier 
method, and differences were tested with the log-rank test. Poten-
tial correlations between CTC findings and the clinicopathologi-
cal characteristics of the patients were tested using either a   2 test 
or Fisher’s exact test.
 A p value of  ! 0.05 was considered to be statistically signifi-
cant. All analyses were carried out using SPSS (version 17.0, SPSS, 
Chicago, Ill., USA).
 Results 
 Validation of the Multimarker Panel for CTC 
Detection 
 The specificity of the real-time RT-PCR products was 
analyzed by high-resolution gel electrophoresis. Sharply 
defined bands of the correct size (76 bp for  ACTB , 126 bp 
for  KRT19 , 71 bp for  MUC1 , 88 bp for  EPCAM , 78 bp for 
Table 1.  Intron-spanning primer pairs for each selected gene
Marker NM reference Primer sequence Location Product size, bp
KRT19 NM_002276.2 forward
reverse
GCCACTACTACACGACCATCC
CAAACTTGGTTCGGAAGTCAT
525–545, exon 1
650–630, exon 2/3
126
MUC1 NM_002456.4 forward
reverse
TCGTAGCCCCTATGAGAAGG
CCACTGCTGGGTTTGTGTAA
795–814, exon 7/8
865–846, exon 8
71
EPCAM NM_002354.2 forward
reverse
CGTCAATGCCAGTGTACTTCA
TTTCTGCCTTCATCACCAAA
448–508, exon 2
575–553, exon 3
88
CEACAM5 NM_004363.2 forward
reverse
ACCACAGTCACGACGATCAC
CTCCACGGGGTTGGAGTT
1052–1071, exon 4
1129–1112, exon 5
78
BIRC5 NM_001168.2 forward
reverse
GCCCAGTGTTTCTTCTGCTT
CCGGACGAATGCTTTTTATG
284–303, exon 2
369–350, exon 3
86
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 CEACAM5 and 86 bp for  BIRC5 ) were obtained for the 
PCR products of the analyzed genes ( fig. 1 ), and primer 
dimers were found to be present in cDNA samples tested 
for  KRT19 and  BIRC5. Bands visible after electrophoresis 
were concordant with the real-time RT-PCR results ob-
tained.
 To determine the linearity, efficiency and analytical 
sensitivity of the multimarker real-time RT-PCR assay, 
we analyzed serial 10-fold dilutions of a cDNA pool of 
human PBLs and ZE tumor cells in 5 different experi-
ments for the 5 tumor-associated transcripts KRT19 , 
 MUC1 ,  EPCAM ,  CEACAM5 and  BIRC5. Calibration 
curves from these data showed linearity over the entire 
quantification range (1–10 4 tumor cells) and R 2  6 0.99 in 
all of the cases, indicating a precise log-linear relation-
ship. The PCR efficiency for the multimarker panel, ex-
pressed as E = 10 –1/slope , ranged from 96 to 104% (data not 
shown). The analytical sensitivity was estimated as the 
last serial linear concentration that yielded positives in all 
5 replicates, and the corresponding Cq value was selected 
as the analytical cutoff. According to the results obtained, 
the analytical Cq cutoff, under which a sample was con-
sidered to be positive for the corresponding marker gene, 
was 36.0 for KRT19, 37.1 for MUC1, 36.0 for EPCAM, 37.8 
for CEACAM5  and 35.0 for BIRC5 .
 Sample Quality 
 The assessment of sample quality and RNA integrity 
are critical steps in obtaining meaningful gene expres-
sion data. Working with low-quality RNA may strongly 
compromise the acquisition of reliable results. Therefore, 
experiments were performed in order to establish a 
threshold criterion that delineates the sample quality and 
integrity sufficient to yield reliable results.
 Random samples were tested for the leukocyte marker 
CD45. Results revealed that in all the samples with an 
 ACTB Cq value  1 30.0, no CD45 amplification was found. 
This indicates that at  ACTB Cq values higher than 30.0, 
the RNA integrity is fully compromised. Therefore, a to-
tal of 6 healthy blood donor samples and 2 patient sam-
ples were excluded from this study because their  ACTB 
Cq value was  1 30.0. Moreover, in order to evaluate false-
positive marker expression due to unspecific background 
levels of mononucleated cells, samples containing differ-
ent concentrations of lymphocytes were tested for the 
multimarker panel. Real-time RT-PCR analysis of sam-
ples containing 10 3 PBLs presented a mean  ACTB Cq val-
ue of 26.2 (range 24.1–27.4) and showed no amplification 
of any of the marker genes used in the present study. On 
the other hand, in samples containing 10 4 PBLs, unspe-
cific amplification of the markers  MUC1, EPCAM and 
 BIRC5 was found. These samples presented  ACTB Cq val-
ues ranging from 21.1 to 24.0. Therefore, in order to avoid 
M ACTB
76 bp
KRT19
126 bp
MUC1
71 bp
EPCAM
88 bp
CEACAM5
78 bp
BIRC5
86 bp
M
a
M ACTB
76 bp
KRT19
126 bp
MUC1
71 bp
EPCAM
88 bp
CEACAM5
78 bp
BIRC5
86 bp
M
b
 Fig. 1. Electrophoresis gel analysis of representative RT-PCR results for a CTC-positive pancreatic cancer patient 
( a ) and a CTC-negative pancreatic cancer patient ( b ). Lane M: 50-bp ladder DNA size marker (Fermentas, St. 
Leon-Rot, Germany). 
 CTCs in Pancreatic Cancer   Oncology 2012;82:3–10 7
false-positive results due to lymphocyte contamination, a 
total of 3 patient samples with  ACTB Cq values below 24.0 
were excluded from this study.
 Patient Characteristics 
 Between April 2009 and June 2011, a total of 40 pa-
tients were enrolled, 34 of whom met the inclusion and 
exclusion criteria [5 patients had to be excluded due to 
poor sample quality (inadequate  ACTB Cq value) and 1 
patient was excluded due to a history of previous malig-
nant disease]. During the median follow-up period of 380 
days (range 61–789), evidence of disease progression was 
documented in 23 patients and death had occurred in 9 
patients. Detailed clinicopathological characteristics of 
the patients are given in  table 2 .
 CTCs at Baseline 
 At baseline, 47.1% of patients showed amplification 
of at least one tumor-associated marker mRNA in their 
PB sample. Positivity rates for each individual marker 
were as follows: 20.6% for  KRT19 and  MUC1 , 23.5% for 
 EPCAM , 2.9% for  CEACAM5 and 17.6% for  BIRC5. A to-
tal of 20.6% of the patients were positive for more than 
one marker. No amplification of the marker genes was 
seen in the 40 healthy controls. Detailed baseline CTC 
results can be seen in  table 3 .
 Correlation between CTCs and Clinicopathological 
Features 
 The presence of CTCs in the PB of pancreatic cancer 
patients at baseline did not correlate with gender, stage, 
tumor size, lymph nodes or metastasis. However, CTC 
positivity was slightly correlated with a higher histologi-
cal tumor grading.
 Correlation between CTCs and PFS in Pancreatic 
Cancer Patients  
 The correlation between PFS and baseline CTC status 
in pancreatic cancer patients was compared with the 
Kaplan-Meier method, and differences were tested using 
the log-rank test. PFS was calculated for groups defined 
by the presence or absence of CTCs before initiating che-
motherapy ( fig. 2 ). Overall median PFS was 120.0 days 
(95% CI 89.4–150.6), while shorter median PFS was ob-
served for patients who had at least one detectable tumor-
associated transcript, compared with patients who were 
CTC negative. Median PFS time was 66.0 days (95% CI 
44.8–87.2) for CTC-positive patients and 138.0 days (95% 
CI 124.1–151.9) for CTC-negative patients (p = 0.01, log-
rank test).
 In order to evaluate whether different marker combi-
nations would also correlate with PFS, we calculated PFS 
for patients with different combinations of positive CTC 
markers, as follows: when only  KRT19 was positive, p = 
0.068; when only  MUC1 was positive, p = 0.273; when on-
ly  EPCAM was positive, p = 0.174; when only  CEACAM5 
was positive, p = 0.196; when only  BIRC5 was positive,
p = 0.044; when  KRT19 or  MUC1 was positive, p = 0.014; 
when  KRT19 or  EPCAM was positive, p = 0.042; when 
 MUC1 or  EPCAM was positive, p = 0.051, and when 
 KRT19, MUC1 or  EPCAM was positive, p = 0.006.
 Discussion 
 To the best of our knowledge, here we report the first 
study using mucin 1- and EpCAM-based immunomag-
netic enrichment, followed by real-time RT-PCR analysis 
of  KRT19 ,  MUC1 ,  EPCAM ,  CEACAM5 and  BIRC5, as a 
way to detect CTCs in PB of pancreatic cancer patients 
and to evaluate their prognostic effect. 
Table 2.  Clinicopathological characteristics of the pancreatic can-
cer patients
Variable All 
pancreatic
cancer 
patients
C TCs p value
pos-
itive
neg-
ative
Total patients, n 34 16 18  
Age at study
entry, years
median 66.9  
range 55–74    
Gender female 14 6 8 0.738
male 20 10 10
Tumor stage II 4 2 2 0.389
III 2 0 2
IV 28 15 13
Tumor size T2 5 1 4 0.395
T3 14 7 7
T4 15 8 7
Lymph nodes N1 4 1 3 0.791
N2 30 15 15
Histology grade G2 24 8 16 0.042
G3 9 7 2
G4 1 1 0
Metastasis yes 28 14 14 0.660
no 6 2 4
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 Despite the progress in pancreatic cancer treatment 
by the application of new chemoradioimmunotherapy 
protocols, the high recurrence rate is the most limiting 
factor for the improvement of patients’ prognosis  [16] . 
Current methods for the detection of recurrence or me-
tastasis in the postoperative period rely on serum tumor 
markers  [17, 18] and imaging modalities, which include 
radiography, computed tomography, magnetic reso-
nance imaging and sonography  [19, 20] . However, these 
prognostic methods lack sensitivity and often do not al-
low for a more personalized approach to cancer treat-
ment. Therefore, more sensitive staging methods capa-
ble of identifying patients who are destined to progress 
quickly or would benefit from more aggressive therapy 
are urgently needed for pancreatic cancer. Minimal re-
sidual disease caused by the spread of tumor cells into 
the circulation is discussed as a major reason for early 
metastases and local recurrence in pancreatic cancer. In 
recent years, only a few studies employing different 
methodologies for CTC isolation and detection  [12, 21–
Table 3.  Detailed CTC data for the analyzed pancreatic cancer 
patients and healthy blood donor controls
Pa-
tient
ID
Re-
sponse
CTC 
status
C TC Cq value cutoff
ACTB 
(24.0–
30.0) 
KRT19
(36.0)
MUC1
(37.1)
EPCAM 
(36.0)
CEACAM5
(37.8)
BIRC5
(35.0)
66.1 PD P 28.9 35.4 36.2 35.5 n.s. n.s.
76.2 PD N 27.3 n.s. n.s. n.s. n.s. n.s.
77.1 PD N 26.3 n.s. n.s. n.s. n.s. n.s.
113.1 death P 29.3 n.s. n.s. 33.1 n.s. 35.1
136.2 PD N 26.9 n.s. 39.1 n.s. n.s. 35.8
148.1 PD N 27.8 n.s. 39.1 n.s. n.s. n.s.
154.1 PD N 29.2 n.s. n.s. n.s. n.s. 35.7
154.7 PD N 29.3 n.s. n.s. n.s. n.s. n.s.
167.1 PD P 26.5 n.s. 36.3 34.1 36.9 34.9
179.1.1 PD P 28.5 n.s. n.s. n.s. n.s. 33.9
179.4 PD N 27.4 n.s. n.s. n.s. n.s. n.s.
203.1 death P 28.1 33.6 n.s. 34.9 n.s. 35.9
209.1 PD N 27.6 n.s. n.s. n.s. n.s. n.s.
210.1 PD P 27.3 31.9 n.s. n.s. n.s. 34.5
211.1 PD N 28.4 n.s. 39.3 n.s. n.s. 35.9
231.1 death P 27.5 35.8 n.s. n.s. n.s. n.s.
242.1 death N 29.2 n.s. n.s. n.s. n.s. n.s.
246.1 death P 27.5 34.0 n.s. n.s. n.s. 35.6
261.1 death N 27.2 n.s. n.s. 36.7 n.s. n.s.
262.1 PD P 26.7 n.s. 34.7 33.3 n.s. 33.8
267.1 death N 28.2 n.s. n.s. n.s. n.s. n.s.
275.1 PD N 28.8 n.s. n.s. n.s. n.s. n.s.
278.1 death N 27.6 n.s. n.s. n.s. n.s. n.s.
295.1 PD P 25.6 34.7 35.0 34.2 n.s. n.s.
297.1 PD N 28.4 n.s. n.s. n.s. n.s. n.s.
298.1 PD P 25.8 n.s. 35.0 34.0 n.s. 35.2
299.1 PD N 28.9 n.s. n.s. n.s. n.s. n.s.
300.1 death P 27.6 n.s. n.s. 36.6 n.s. 34.8
313.1 SD N 28.9 n.s. n.s. n.s. n.s. n.s.
330.1 PD P 29.1 34.9 n.s. n.s. n.s. n.s.
345.1 PD P 29.0 n.s. 37.0 n.s. n.s. n.s.
356.1 PD P 28.6 n.s. 35.7 36.9 n.s. n.s.
369.1 SD P 27.8 n.s. n.s. 35.0 n.s. 34.1
211.8 PD N 29.0 n.s. n.s. n.s. n.s. n.s.
Healthy blood 
donor controls1
28.6
81.2
n.s. 38.5
80.6
36.9
80.8
n.s. 35.7
80.5
In  the healthy blood donor controls, 7 probes gave a positive 
signal for MUC1, 11 probes for EPCAM and 6 for BIRC5. The 
mean 8 SD values were calculated using only these probes. All 
the Cq values obtained in the healthy blood donor controls were 
under the defined CTC positivity cutoffs. PD = Progressive dis-
ease; SD = stable disease; P = positive; N = negative; n.s. = no sig-
nal of the gene found during the 40 PCR cycles.
1 Cq values represent the mean 8 SD of the 40 analyzed sam-
ples.
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 Fig. 2. PFS of pancreatic cancer patients with and without CTCs 
in 10 ml of blood before therapy (CTC positivity is defined by 
positivity of at least one marker gene). In the present study, the 
time to event data was measured as the time between the baseline 
of the blood sampling for CTC analysis and the documentation of 
death or first tumor progression based on clinical and radiologi-
cal studies. Patients who were alive and progression free at the 
time of analysis were censored using the time between the base-
line CTC assessment and their most recent follow-up evaluations. 
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27] have focused on the isolation and identification of 
CTCs in PB of pancreatic cancer patients, with some of 
them reporting contradictory results concerning the 
prognostic significance of CTCs. Soeth et al.  [25] detect-
ed CK20-positive mRNA transcripts in the PB of 33.8% 
(52/154) of pancreatic cancer patients before operation 
and showed a statistically significant relationship be-
tween overall survival and the detection of CTCs in PB. 
Zhou et al.  [26] reported that the combined analysis of 
C-MET, h-TERT, CK20 and CEA could detect CTCs in 
the PB blood of 100% (25/25) of pancreatic cancer pa-
tients before operation, radiotherapy and chemotherapy, 
with 100% specificity. Finally, Sergeant et al.  [27] report-
ed that no association was found between EpCAM posi-
tivity in PB of pancreatic ductal adenocarcinoma pa-
tients (n = 48) and cancer-specific or disease-free sur-
vival; nor were significant correlations found between 
clinicopathological variables and perioperative EpCAM 
positivity.
 In the present pilot study, we report the development 
of an immunomagnetic/real-time RT-PCR assay for 
CTC detection and characterization. Our data suggest 
that CTCs identified by this methodology can serve as a 
prognostic factor for pancreatic cancer patients begin-
ning systemic treatment. The assay described herein pro-
vides a specific and sensitive method for isolation and 
identification of CTCs in PB of pancreatic cancer pa-
tients. CTCs were immunomagnetically enriched by 
coupling magnetic beads to the specific antibodies 
VU1D9 and BM7, with high affinity for the antigens 
EpCAM and mucin-1, respectively. By adding a second 
antibody targeting mucin-1, we have increased the 
chances for CTC isolation in comparison with solely 
EpCAM-based enrichment systems. All EpCAM-based 
assays share the same limitation, namely that EpCAM is 
expressed in most but not all tumors  [28] . Several studies 
have found that EpCAM can be either upregulated or 
downregulated during cancer progression and metasta-
sis  [29, 30] . Moreover, the real-time RT-PCR assay devel-
oped here showed high specificity, as none of the healthy 
controls were found to be positive for the multimarker 
gene panel. In addition, by preparing a standard curve 
for each gene, we determined the linearity, efficiency and 
analytical sensitivity of the assay. Subsequently, Cq cut-
off values for each gene were created, so as to guarantee 
that no Cq value above the corresponding reliable ana-
lytical limit of detection of the assay was considered pos-
itive  [15] . 
 When applied in the clinic, the present assay revealed 
that 47.1% of pancreatic cancer patients showed amplifi-
cation of at least one tumor-associated marker mRNA in 
their PB sample. Furthermore, our results demonstrate 
that the presence of at least one clearly detectable tumor-
associated transcript in the PB of pancreatic cancer pa-
tients is a strong predictive factor for shorter PFS. Patients 
who were CTC positive before treatment had significant-
ly reduced disease-free survival time compared with pa-
tients who were CTC negative. Moreover, CTC findings 
were also correlated with tumor grading. As expected, we 
observed that the CTC detection rate was significantly 
increased when a multimarker panel was applied com-
pared with the results obtained using single markers. 
Metastatic tumors are particularly heterogeneous, and 
therefore, the combination of marker genes can compen-
sate for variations in individual marker expression, in-
creasing the chances of CTC detection  [31] . Moreover, 
multimarker analysis of CTCs allows for characterization 
of these malignant cells in terms of aggressiveness and 
phenotype  [32] . This may further promote the selection 
of the most effective treatment and the creation of truly 
tailored therapy regimes. 
 The limitations of this work must be considered. The 
study population was relatively small, which may influ-
ence the interpretation of the results. However, small well-
designed studies are of great value as they can provide 
results quickly and can thus become part of a first selec-
tion in order to design further, larger confirmatory stud-
ies. 
 In conclusion, our results suggest that in addition to 
the current prognostic methods for pancreatic cancer, 
CTC analysis represents a potential complementary tool 
for prediction of patient outcome and may ultimately en-
able the creation of tailored therapy and improved patient 
care.
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